The Tampa-based biotech is currently advancing its lead innate immune agonist, IFx-2.0, which is undergoing a randomized Phase 3 registration trial. The study evaluates the candidate as an adjunctive therapy alongside pembrolizumab for patients diagnosed with advanced or metastatic Merkel Cell Carcinoma. By targeting primary resistance, the company aims to improve outcomes for patients who do not respond to standard checkpoint inhibitors.
TuHURA Biosciences CEO to Present at Canaccord Genuity Growth Conference
James A. Bianco, president and CEO of TuHURA Biosciences, will outline the company's progress in immuno-oncology at the 46th Annual Canaccord Genuity Growth Conference in Boston. The presentation, scheduled for August 12, 2026, highlights the firm’s strategy to address resistance in cancer immunotherapy treatments.
Beyond its lead program, TuHURA is developing TBS-2025, a VISTA-inhibiting monoclonal antibody entering Phase 1b trials for a specific subset of acute myeloid leukemia. The company’s pipeline also includes bi-specific antibody drug conjugates designed to neutralize immune-suppressing cells within the tumor microenvironment. Investors can access the presentation via a live webcast or review the archived version through the investor section of the company’s official website.
Comments (0)
No comments yet. Be the first!